4-[(11S)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-2-yl]piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[(11S)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-2-yl]piperazine-1-carboxylic acid
• 化学式: C₂₄H₂₄N₆O₄
• 分子量: 460.5
• InChiKey: FWWFVRZGUWHONO-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160075721A1

  公开（公告）日：2016-03-17

  The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

  本公开涉及三环杂环化合物，这些化合物是BET蛋白的抑制剂，如BRD2、BRD3、BRD4和BRD-t，并且在治疗癌症等疾病方面具有用处。
• Tricyclic heterocycles as bet protein inhibitors
  申请人：Incyte Corporation

  公开号：US10227359B2

  公开（公告）日：2019-03-12

  The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

  本公开涉及三环杂环，它们是 BET 蛋白（如 BRD2、BRD3、BRD4 和 BRD-t）的抑制剂，可用于治疗癌症等疾病。
• Tricyclic heterocycles as BET protein inhibitors
  申请人：Incyte Corporation

  公开号：US10464947B2

  公开（公告）日：2019-11-05

  The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

  本发明涉及式 (I) 的三环杂环： 它们是 BET 蛋白如 BRD2、BRD3、BRD4 和 BRD-t 的抑制剂，可用于治疗癌症等疾病。
• TRICYCLIC HETEROCYCLES FOR USE AS BET PROTEIN INHIBITORS
  申请人：Incyte Holdings Corporation

  公开号：EP3194406B1

  公开（公告）日：2020-12-16
• TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR
  申请人：Incyte Holdings Corporation

  公开号：EP3581576B1

  公开（公告）日：2022-01-26